| A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. The Flecainide Multicenter Investigators Group. | |
| | |
MedLine Citation:
|
PMID: 8607397 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Reentrant paroxysmal supraventricular tachycardia (PSVT) are frequently encountered in clinical practice. Verapamil and flecainide have both been successfully used as chronic oral therapy to prevent PSVT recurrences. This open-label, randomized, multicenter study was designed to compare the efficacy and adverse effects of verapamil (median dose, 240 mg/day) versus flecainide (median dose, 200 mg/day) in patients with frequent and symptomatic attacks of PSVT (other than atrial fibrillation or flutter). A total of 121 patients receiving flecainide (n = 63) or verapamil (n = 58) were followed for 8.1 +/- 5.1 and 7.5 +/- 5.4 months, respectively. Response was judged clinically as effective or not by the treating physician. By life table analysis, 11% discontinued flecainide and 19% discontinued verapamil for inefficacy at 1 year (difference not significant). Both groups showed a marked reduction in the frequency of attacks of PSVT. Before therapy, 71% of flecainide patients and 73% of verapamil patients had > or = 2 attacks per month. During therapy, 86% of all flecainide patient-months and 73% of all verapamil patient-months occurred with 0 or 1 attack; 19 (30%) patients on flecainide completed the trial ( > 270 days) without symptomatic attacks versus 7 (13%) of the patients on verapamil (p = 0.026). Both drugs were well tolerated; 19% of the flecainide group discontinued primarily because of adverse effects, compared with 24% discontinuing verapamil for this reason (difference not significant). Both flecainide and verapamil are effective and well tolerated for the prevention of recurrences of PSVT. For patients in whom radiofrequency ablation procedures cannot be performed or are not indicated, either therapy is a reasonable choice for long-term prophylaxis. |
| | |
Authors:
|
P Dorian; G V Naccarelli; P Coumel; S H Hohnloser; M J Maser |
Related Documents
:
|
7850817 - Probability of supraventricular tachycardia recurrence in pediatric patients. 18404727 - Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. 1736607 - Identification of patients at high risk for recurrence of sustained ventricular tachyca... 3711517 - Perioperative and long-term results after electrophysiologically directed ventricular s... 8769327 - Contemporary total hip replacement with metal on metal articulation. 18338217 - Curved-stem hip resurfacing: minimum 20-year followup. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The American journal of cardiology Volume: 77 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 1996 Jan |
Date Detail:
|
Created Date: 1996-05-23 Completed Date: 1996-05-23 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 89A-95A Citation Subset: AIM; IM |
Affiliation:
|
St. Michael's Hospital, University of Toronto, Ontario, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adult Aged Anti-Arrhythmia Agents / administration & dosage, adverse effects, therapeutic use* Electrocardiography Female Flecainide / administration & dosage, adverse effects, therapeutic use* Humans Life Tables Male Middle Aged Recurrence Tachycardia, Paroxysmal / drug therapy* Tachycardia, Supraventricular / drug therapy* Verapamil / administration & dosage, adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Arrhythmia Agents; 52-53-9/Verapamil; 54143-55-4/Flecainide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricula...
Next Document: Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction wi...